ArticleKidney medicine2025
Association Between Relapse and Long-Term Kidney Outcomes in IgA Nephropathy.
Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting tissue immune memory in chronic-remitting autoimmune kidney diseases: current concepts and future therapies.Clinical kidney journal · 2026Review
- Effectiveness and Safety of Nefecon in Primary IgA Nephropathy Across Different Baseline Proteinuria Levels: A Real-World Study.Advances in therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: Relapse in IgA nephropathy (IgAN) remains under-researched. This study investigates the incidence of IgAN relapse, its association with adverse outcomes, and its risk factors within a prospective cohort. Study Design: Prospective cohort study. Setting & Participants: The study included 1,069 patients with IgAN who achieved remission following treatment. Predictor: Relapse or not after remission of IgAN. Outcomes: The first occurrence of either end-stage kidney disease (estimated glomerular filtration rate [eGFR] <15 mL/min/1.73 m Analytical Approach: We assessed relapse incidence, its correlation with kidney endpoint events, and identified clinicopathological predictors of relapse using Cox regression analysis. Least Absolute Shrinkage and Selection Operator Cox regression was performed to screen predictive variables to predict relapse. Results: Among the 1,069 patients, 348 (33%) experienced 411 relapses. The overall relapse-free rates at 1, 5, and 10 years were 93%, 65%, and 48%, respectively. Relapse patients had a significantly higher incidence kidney endpoint events compared with nonrelapse patients. The relapse group also exhibited a more rapid decline in eGFR compared with the nonrelapse group (-2.3 vs -1.0 mL/min/1.73 m Limitations: Single-center study; no standardized definition for IgAN remission and relapse. Conclusions: Relapse is prevalent in IgAN and is associated with an increased rate of kidney endpoint events and accelerated eGFR decline. Predictors of relapse encompass various clinicopathological indicators and medications, with stricter control of proteinuria at remission being crucial for reducing relapse rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.